References
- Jolivet J, Cowan K H, Curt G A. The pharmacology and clinical use of methotrexate. N Engl J Med 1983; 309: 1094–1104
- Evans W E, Hutson P R, Stewart C F. Methotrexate cerebrospinal fluid and serum concentrations after intermediate dose methotrexate infusion. Clin Pharmacol Ther 1983; 33: 301–307
- Poplack D G, Reaman G H, Bleyer W A. Central nervous system (CNS) preventive therapy with high dose methotrexate (HDMTX) in acute lymphoblastic leukemia (ALL): A preliminary report. Proceedings of the 16th Annual Congress of the International Society of Pediatric Oncology. International Society of Pediatric Oncology, Barcelona 1984; 35
- Bratlid D, Moe P J. Pharmacokinetics of high-dose methotrexate treatment in children. Eur J Clin Pharmacol 1978; 14: 143–147
- Luyckx M, Cazin J L, Brunet C. Clinical pharmacokinetics of 6-hour infusion of high-dose methotrexate. Preliminary trial of monitoring high infusion doses. Eur J Clin Pharmacol 1985; 28: 457–462
- Evans W E, Pratt C B, Taylor R H. Pharmacokinetic monitoring of high-dose methotrexate: Early recognition of high-risk patients. Cancer Chemother Pharmacol 1979; 3: 161–166
- Jacobs S A, Stoller R G, Chabner B A. 7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. J Clin Invest 1976; 57: 534–538
- Breithaupt H, Kuenzlen E. Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following high-dose methotrexate. Cancer Treat Rep 1982; 66: 1733–1741
- Wang Y-M, Fujimoto T. Clinical pharmacokinetics of methotrexate in children. Clin Pharmacokinet 1984; 9: 335–348
- Erttman R, Bielack S, Landbeck G. Kinetics of 7-hydroxymethotrexate after high-dose methotrexate therapy. Cancer Chemother Pharmacol 1985; 15: 101–104
- Djerassi I, Kim J S, Nayak N P. High-dose methotrexate with citrovorum factor rescue: A new approach to cancer chemotherapy. Recent Advances in Cancer Chemotherapy, HJ Taagnon, MJ Staquet. Raven Press, New York 1977; 201–225
- Erttmann R, Bielack S, Landbeck G. 7-Hydroxymethotrexate and clinical toxicity following high-dose methotrexate therapy. J Cancer Res Clin Oncol 1985; 109: 86–88
- Slørdal L, Prytz P S, Pettersen I. Methotrexate measurements in plasma. Comparison of EMIT, TDX, and HPLC. Ther Drug Monit, in press
- Campbell M A, Perrier D G, Dorr R T. Methotrexate: Bioavailability and pharmacokinetics. Cancer Treat Rep 1985; 69: 833–838
- Newton P A, Blakley R L. 7-Hydroxymethotrexate formation in a human lymphoblastic cell line. Biochem Biophys Res Commun 1984; 122: 1212–1217
- Høyem-Johansen T, Slørdal L, Høylandskjaer A. The effect of antineoplastic drugs on the pharmacokinetics of antipyrine in the rat. Acta Pharmacol Toxicol 1980; 47: 279–284
- Slørdal L, Høyem-Johansen T, Aarbakke J. Microsomal metabolism of antipyrine in rats treated with antineoplastic drugs. Pharmacology 1983; 26: 95–99
- Gaukroger J M, Wilson L. Protection of cells from methotrexate toxicity by 7-hydroxymethotrexate. Br J Cancer 1984; 50: 327–333
- Fabre G, Goldman I D. Formation of 7-hydroxymethotrexate polyglutamyl derivatives and their cytotoxicity in human chronic myelogenous leukemia cells, in vitro. Cancer Res 1985; 45: 80–85